XB.2.2 / AbelZeta Pharma - LARVOL DELTA

Unaltered NKG2D-CAR T cell function under hypoxia in osteosarcoma in vitro. (PubMed, Cancer Immunol Immunother) - "Crucially, functional assays demonstrated that NKG2D-CAR T cell phenotype, activity, and cytokine secretion remained unaffected and its activity against three-dimensional OS-spheroids was preserved under in vitro hypoxic conditions. Although these findings challenge the idea that hypoxia alone compromises in vitro NKG2D-CAR T efficacy in OS, further studies are needed on how hypoxia interacts with multiple factors of the TME that could modulate CAR T cell behavior."

IO biomarker • Journal • Preclinical • Oncology • Osteosarcoma • Pediatrics • Sarcoma • Solid Tumor • HIF1A • NKG2D

Dasatinib improves NKG2D-CAR T cell manufacturing and function for the treatment of osteosarcoma (ESGCT 2025) - No abstract available

CAR T-Cell Therapy • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

Synergistic immunotherapy for osteosarcoma: enhancing NKG2D-CAR T cell efficacy with armed oncolytic adenoviruses (ESGCT 2025) - No abstract available

CAR T-Cell Therapy • Clinical • Oncolytic virus • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D

LIN28 upregulation in primary human T cells impaired CAR T antitumoral activity. (PubMed, Front Immunol) - "LIN28 overexpression maintained human T cell phenotype markers and functionality but impaired the antitumoral cytotoxicity of NKG2D-CAR T cells both in vitro and in vivo. These findings highlight the intricate relationship between LIN28/let-7 axis and human T cell functionality, including in CAR T cell therapy."

IO biomarker • Journal • Infectious Disease • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • NKG2D